EverSource Wealth Advisors LLC Acquires 709 Shares of Organon & Co. (NYSE:OGN)

EverSource Wealth Advisors LLC increased its holdings in shares of Organon & Co. (NYSE:OGN) by 16.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,030 shares of the company’s stock after acquiring an additional 709 shares during the period. EverSource Wealth Advisors LLC’s holdings in Organon & Co. were worth $94,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Organon & Co. by 0.6% during the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after buying an additional 192,613 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Organon & Co. by 10.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 10,211,008 shares of the company’s stock valued at $147,243,000 after acquiring an additional 930,708 shares during the period. Sound Shore Management Inc. CT increased its holdings in shares of Organon & Co. by 35.2% in the 4th quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock valued at $67,415,000 after acquiring an additional 1,216,522 shares during the period. LSV Asset Management increased its holdings in shares of Organon & Co. by 34.0% in the 1st quarter. LSV Asset Management now owns 4,488,828 shares of the company’s stock valued at $84,390,000 after acquiring an additional 1,139,249 shares during the period. Finally, Nordea Investment Management AB increased its holdings in shares of Organon & Co. by 26.9% in the 1st quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company’s stock valued at $74,563,000 after acquiring an additional 841,518 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 6.8 %

OGN traded down $1.37 during trading hours on Tuesday, reaching $18.82. The company’s stock had a trading volume of 5,052,825 shares, compared to its average volume of 2,271,954. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The stock has a market cap of $4.84 billion, a PE ratio of 4.51, a P/E/G ratio of 1.01 and a beta of 0.85. The business’s 50-day moving average is $20.87 and its 200-day moving average is $19.26. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15.

Wall Street Analysts Forecast Growth

OGN has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price target on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Piper Sandler boosted their price objective on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, April 29th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.